OUR PURPOSE IS SIMPLE:
Patients fighting chronic diseases are often denied access to life-saving treatments.
ICERWatch gives patients a voice to fight back.
What Is ICER?
It's Important for Patients to Know
An organization most patients never heard of is now hard at work determining whether recently approved drugs for serious and often life-threatening diseases should be covered by private health plans and made available to patients. Called the Institute for Clinical and Economic Review (ICER), this Boston-based institute describes itself as “a trustworthy, independent source to help assess how valuable a new drug really is.” Yet, ICER has come under increasing criticism due to the methods it uses to decide the “value” of new medicines, and its ultimate purpose of limiting the use of drugs patients and clinicians need.
A new treatment for treatment-resistant depression, esketamine, is offering hope to patients. Now, insurance-backed ICER is trying to block patient access.
The Institute for Clinical and Economic Review (ICER) posted a white paper[i]that attempts to provide insights into how rebates on prescription drugs is increasing costs